In addition, monitoring of white blood cell counts, renal function ... no skin tumors, no lymph nodes or visceral involvement IB: >10% body surface area involved, otherwise same as IB IIA ...

cutaneous T-cell lymphoma, and it is FDA approved for these indications. The mechanism of action has not been fully elucidated. It is likely that photopheresis activates antigen-presenting cells ...

therapy for up to 12 months in patients with early-stage cutaneous T-cell lymphoma was provided by Soligenix, Inc. · In June 2024: Innate Pharma SA released encouraging results from the Phase 2 ...

Symptom control is often the goal for patients who have mycosis fungoides, the most common type of cutaneous T-cell lymphoma. Mycosis fungoides tends to advance slowly, so symptom control can help you ...

Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR) and its oncology-focused subsidiary, Citius ...

University of Queensland research using natural killer cells may lead to the first new treatment for a devastating childhood ...

THIO sequenced with Libtayo extended overall survival in those with non–small cell lung cancer who progressed on two or more ...

adding to its earlier approvals for diffuse large B-cell lymphoma (DLBCL) and acute lymphoblastic leukaemia. Kymriah was the first CAR-T to reach the market in 2017, but was closely followed by ...

We're dedicated to conducting cutting-edge, fundamental basic and translational research to improve human health and educating the next generation of scientists. Our faculty, staff, and trainees play ...

A small but in-depth study of allogeneic CAR T cell therapy in patients with high-risk neuroblastoma shows feasibility and potential efficacy, and mechanistic insights reveal pathways to improved ...